Deka Bank Deutsche Girozentrale Prothena Corp Public LTD CO Transaction History

Deka Bank Deutsche Girozentrale

$53.9 Billion
Q3 2024

A detailed history of Deka Bank Deutsche Girozentrale transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 14,000 shares of PRTA stock, worth $222,320. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,000

Previous 14,000 -0.0%

Holding current value

$222,320

Previous $285,000 2.81%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	BUY	$30.27 - $49.22 $39,351 - $63,986	1,300 Added 10.24%	14,000 $511,000
Q4 2021 Feb 02, 2022	BUY	$42.11 - $73.26 $14,738 - $25,641	350 Added 2.83%	12,700 $582,000
Q3 2020 Oct 29, 2020	BUY	$9.93 - $13.47 $122,635 - $166,354	12,350 New	12,350 $119,000
Q4 2019 Feb 04, 2020	SELL	$7.48 - $17.01 $94,622 - $215,176	-12,650 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$6.89 - $10.45 $87,158 - $132,192	-12,650 Reduced 50.0%	12,650 $99,000
Q2 2019 Aug 01, 2019	BUY	$8.85 - $12.49 $87,172 - $123,026	9,850 Added 63.75%	25,300 $255,000
Q1 2019 May 10, 2019	BUY	$10.32 - $14.49 $28,896 - $40,572	2,800 Added 22.13%	15,450 $240,000
Q4 2018 Feb 12, 2019	SELL	$8.73 - $13.74 $24,444 - $38,472	-2,800 Reduced 18.12%	12,650 $131,000
Q3 2018 Nov 09, 2018	SELL	$12.7 - $15.79 $5,080 - $6,316	-400 Reduced 2.52%	15,450 $0
Q1 2018 May 03, 2018	SELL	$27.95 - $45.04 $176,085 - $283,752	-6,300 Reduced 28.44%	15,850 $579,000
Q3 2017 Nov 06, 2017	BUY	$53.83 - $67.75 $1.19 Million - $1.5 Million	22,150	22,150 $1.28 Million

Others Institutions Holding PRTA

# of Institutions

184

Shares Held

42.7M

Call Options Held

162K

Put Options Held

102K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $745M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.

Account

Deka Bank Deutsche Girozentrale Prothena Corp Public LTD CO Transaction History